PROJECT SUMMARY/ABSTRACT
The human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer ((gp120-gp41)3) binds to host
receptors, CD4 and CCR5/CXCR4, and mediates the entry of the virus into the target cell. CD4 binding induces
large-scale conformational changes in the metastable Env trimer, resulting in transitions from a pretriggered,
“closed” conformation to more “open” conformations. The CD4-induced opening of the Env trimer allows the
gp120 subunit to bind the CCR5/CXCR4 coreceptor, which enables the fusion of viral and target cell membranes
by the gp41 transmembrane subunit.
CD4-mimetic compounds (CD4mcs) are small organic molecules that bind to a highly conserved pocket (the
Phe-43 cavity) on gp120, near the binding site for CD4. CD4mcs competitively block CD4 binding and
prematurely trigger conformational changes in Env similar to those induced by CD4. In the absence of a
coreceptor-expressing target cell, these prematurely activated Envs rapidly and irreversibly become non-
functional. At sub-inhibitory concentrations, CD4mcs open Env to the binding of antibodies that consequently
acquire neutralizing or cytotoxic potential. CD4mcs can synergize with antibodies to decrease the HIV-1-infected
cell reservoir in humanized mice and to protect monkeys from a heterologous SHIV mucosal challenge.
The CD4mc scaffold, which occupies the gp120 “vestibule” leading into the Phe-43 cavity, is a critical determinant
of the antiviral potential of these compounds. Replacing the tetramethyl-piperidine scaffold of the prototypic
CD4mcs with an indane scaffold opened the door to rationally designed improvements in antiviral potency and
breadth. Nonetheless, some primary HIV-1 strains with apparently accessible Phe-43 cavities remain relatively
resistant to current lead indane CD4mcs. We have recently identified novel CD4mc analogues with indoline
scaffolds that demonstrate impressive increases in antiviral potency and breadth. In this proposal, we capitalize
on this discovery to design further improvements in the indoline CD4mcs, to investigate the mechanisms
underlying their antiviral potency, and to determine how natural HIV-1 Env variation influences virus resistance
to CD4mcs and viral replication fitness. In the course of these studies, we will test the following hypotheses:
Hypothesis 1: Increasing the contacts of the indoline CD4mcs with conserved gp120 elements in the vestibule
will further enhance their antiviral potency and breadth; Hypothesis 2: Although CD4mc resistance in a small
subset of HIV-1 strains results from variation within the Phe-43 cavity, the sensitivity of most primary HIV-1
strains to CD4mcs is governed by differences in Env triggerability (the propensity of the Env to undergo
conformational change); and Hypothesis 3: CD4mcs gain potency by enhanced binding to the Env trimer,
leading to sequential activation and inactivation that ultimately result in gp120 shedding.
The knowledge generated by testing these hypotheses will assist efforts to improve the antiviral efficacy of
CD4mcs and will enhance their utility as small-molecule probes of HIV-1 Env conformation.